

References

I-42

1. Banys M, Solomayer EF, Gebauer G, et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. *BMC Cancer*. 2013 Oct 15;13(1):480.
2. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. *Ann Oncol*. 2013;24(2):398-405.
3. Coleman RE, Gregory W, Marshall H, et al. The metastatic microenvironment of breast cancer: Clinical implications. *Breast*. 2013 Aug;22 Suppl 2:S50-6.
4. Diab DL, Watts NB. Postmenopausal osteoporosis. *Curr Opin Endocrinol Diabetes Obes*. 2013 Oct 21.
5. Eriksen EF, Díez-Pérez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review. *Bone*. 2013 Oct 9. pii: S8756-3282(13)00378-5.
6. He M, Fan W, Zhang X. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: An updated systematic review and meta-analysis. *J Hematol Oncol*. 2013;6(1):80.
7. Kmetec A, Hajdinjak T. Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid. *Radiol Oncol*. 2013 Jul 30;47(3):289-95
8. Koivisto K, Kyllonen E, Haapea M, et al. Efficacy of zoledronic acid for chronic low back pain associated with Modic changes in magnetic resonance imaging. *BMC Musculoskelet Disord*. 2014;15:64.
9. Kumar M, Rastogi A, Bhadada SK, et al. Effect of zoledronic acid on bone mineral density in patients of celiac disease: A prospective, randomized, pilot study. *Indian J Med Res*. 2013;138(6):882-887.
10. Kyrgidis A, Tzellos TG, Toulis K, et al. An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients. *Curr Clin Pharmacol*. 2013;8(2):124-134.
11. Larocca A, Child JA, Cook G, et al. The impact of response on bone-directed therapy in patients with multiple myeloma. *Blood*. 2013; 122(17):2974-2977.
12. Ralston SH. Clinical practice. Paget's disease of bone. *N Engl J Med*. 2013;368(7):644-650.
13. Reclast® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2017.
14. Van den Wyngart T, Delforge M, Doyen C, et al. Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors. *Support Care Cancer* 2013; 21:3483-3490. DOI 10.1007/s00520-013-1934-0.
15. Zhang J, Wang Y, Han K, et al. Percutaneous Vertebroplasty Combined with Zoledronic Acid for the Treatment of Painful Osteolytic Spinal Metastases in Patients with Breast Cancer. *J Vasc Interv Radiol*. 2013 Oct 18. pii: S1051-0443(13)01392-4.

16. Wirth M, Tammela T, Cicalese V, et al. Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS). *EAU*. 2015;482-491.
17. Sun S, Wang F, Dou H, Zhang L, Li J. Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole. *OncoTargets and Therapy*. 2016;6029-6036.
18. Clive AO, Hooper CE, Edey AJ, et al. A Randomised Controlled Trial of Intravenous Zoledronic Acid in Malignant Pleural Disease: A Proof of Principle Pilot Study. *PLoS ONE* 2015;10(3): e0118569.
19. National Comprehensive Cancer Network® (NCCN) Drugs and Biologics Compendium. 2017. Zoledronic acid.
20. Crandall C, Newberry S, Diamant A, et al. Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures: An Updated Systematic Review. *Ann Intern Med*. 2014;161(10):711-723.
21. Kalder M, Kyvernitakis I, Albert U, et al. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy. *Osteoporos Int*. 2015;26:353-360.
22. Valachis A, Polyzos N, Coleman R, et al. Adjuvant Therapy with Zoledronic Acid in patients with Breast Cancer: a Systematic Review and Meta-Analysis. *The Oncologist*. 2013;18:353-361.
23. Zometa® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2016.
24. Clinical Pharmacology Compendia. 2018. Tampa FL: Gold Standard, Inc. Zoledronic Acid. Accessed February 20, 2018.
25. MICROMEDEX® SOLUTIONS Compendia. 2018. Zoledronic Acid. Accessed February 20, 2018.
26. National Comprehensive Cancer Network (NCCN). NCCN Thyroid Carcinoma. Version 2.2017. Accessed February 20, 2018.
27. National Comprehensive Cancer Network (NCCN). NCCN Non-Small Cell Lung Cancer. Version 2.2018. Accessed February 20, 2018.
28. National Comprehensive Cancer Network (NCCN). NCCN Kidney Cancer. Version 3.2018. Accessed February 20, 2018.
29. National Comprehensive Cancer Network (NCCN). NCCN Breast Cancer. Version 4.2017. Accessed February 20, 2018.
30. National Comprehensive Cancer Network (NCCN). NCCN Multiple Myeloma. Version 4.2018. Accessed February 20, 2018.
31. National Comprehensive Cancer Network (NCCN). NCCN Prostate Cancer. Version 1.2018. Accessed February 20, 2018.
32. Camacho P, Petak S, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. *Endocrine Practice*. 2016;22(4):1-42.